Zika virus vaccine - Protein Sciences Corporation
Alternative Names: Zikavirus vaccineLatest Information Update: 01 Sep 2023
At a glance
- Originator Protein Sciences Corporation
- Developer Immunobiological Technology Institute; Laboratorios Liomont; Mundo Sano; National Institute of Allergy and Infectious Diseases; Protein Sciences Corporation; Sinergium Biotech; UMN Pharma
- Class Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Zika virus infection
Most Recent Events
- 01 Sep 2023 Discontinued - Preclinical for Zika virus infection (Prevention) in USA (unspecified route) (Protein Sciences Corporation pipeline; September 2023)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Zika-virus-infection(Prevention) in USA
- 28 Feb 2021 No recent reports of development identified for research development in Zika-virus-infection(Prevention) in Brazil
Development Overview
Introduction
Protein Sciences Corporation (a subsidiary of Sanofi) is developing a Zika virus vaccine, which is a purified protein formulated with alum and based on recombinant variations of E-protein from the virus. The vaccine uses a proprietary Baculovirus Expression Vector System (BEVS) protein expression technology and Spodoptera frugiperda insect cell lines (expresSF+ cells) to generate large quantities of desired recombinant proteins. Early research is underway in Argentina, Brazil, Mexico and Japan. Preclinical development was underway in the US. However, as of September 2023, indication was no longer listed on the company pipeline, therefore, it appears that development has been discontinued for Zika virus infection in the US.
In August 2017, Protein Sciences was acquired by Sanofi [1] .
As at May 2020, no recent reports of development had been identified for research development in Zika-virus-infection (Prevention) in Argentina.
As at July 2020, no recent reports of development had been identified for research development in Zika-virus-infection (Prevention) in Japan.
As at February 2021, no recent reports of development had been identified for research development in Zika-virus-infection (Prevention) in Mexico, Brazil.
Company Agreements
In January 2017, Protein Sciences reported that the Institute of Technology in Immunobiologicals of the Oswaldo Cruz Foundation, also called Bio-Manguinhos/Fiocruz, had joined, in Brazil, the multinational consortium, that is sponsoring development of the Zika virus vaccine. The Zika consortium already consists of four other partners: Mundo Sano and Sinergium Biotech in Argentina, Liomont in Mexico, and UMN Pharma in Japan [2] .
In June 2016, Protein Sciences and UMN entered into an agreement to develop a Zika virus vaccine. Under the terms of the agreement, UMN will pay an upfront fee to fund the development and manufacture of the vaccine being produced at Protein Sciences and receive manufacturing and commercial rights to the vaccine in Japan and other countries to be determined. Further details of the agreement were not disclosed [3] .
In April 2016, Protein Sciences, Sinergium and Mundo Sano entered into an agreement to develop a Zika virus vaccine in Latin America and other countries. Under the terms of the agreement, Sinergium will pay an advance fee to fund the development and manufacture of the vaccine to Protein Sciences. In return, Sinergium will receive manufacturing and commercial rights for the development of the vaccine in Argentina and other countries [4] .
Key Development Milestones
As of September 2023, indication was no longer listed on the company pipeline, therefore, it appears that development has been discontinued for Zika virus infection in the US (Protein Sciences Corporation pipeline; September 2023).
In January 2017, Protein Sciences Corporation reported that its Zika virus vaccine demonstrated safety during a toxicology study sponsored by National Institute of Allergy and Infectious Disease, National Institutes of Health. The vaccine also induced strong neutralising antibodies against the Zika virus in outbred mice during preclinical trials. Based on these data the company is planning to initiate a phase I trial of Zika virus vaccine in the US in April 2017 [2] .
Drug Properties & Chemical Synopsis
- Formulation unspecified
- Class Synthetic vaccines, Viral vaccines
- Mechanism of Action Immunostimulants
-
WHO ATC code
J07B (Viral Vaccines)
-
EPhMRA code
J7E (Viral Vaccines)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Zika virus infection | - | Prevention | No development reported (Research) | Argentina | unspecified / unspecified | Mundo Sano, Sinergium Biotech, Protein Sciences Corporation | 28 May 2020 |
| Zika virus infection | - | Prevention | No development reported (Research) | Japan | unspecified / unspecified | Protein Sciences Corporation, UMN Pharma | 28 Jul 2020 |
| Zika virus infection | - | Prevention | No development reported (Research) | Brazil | unspecified / unspecified | Immunobiological Technology Institute, Protein Sciences Corporation | 28 Feb 2021 |
| Zika virus infection | - | Prevention | No development reported (Research) | Mexico | unspecified / unspecified | Laboratorios Liomont, Protein Sciences Corporation | 28 Feb 2021 |
| Zika virus infection | - | Prevention | Discontinued (Preclinical) | USA | unspecified / unspecified | National Institute of Allergy and Infectious Diseases, Protein Sciences Corporation | 01 Sep 2023 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Protein Sciences Corporation | Originator | USA |
| Protein Sciences Corporation | Owner | USA |
| Sinergium Biotech | Licensee | Argentina |
| Mundo Sano | Collaborator | Argentina |
| Immunobiological Technology Institute | Collaborator | Brazil |
| National Institute of Allergy and Infectious Diseases | Collaborator | USA |
| UMN Pharma | Collaborator | Japan |
| Laboratorios Liomont | Collaborator | Mexico |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 01 Sep 2023 | Phase Change - Discontinued(Preclinical) | Discontinued - Preclinical for Zika virus infection (Prevention) in USA (unspecified route) (Protein Sciences Corporation pipeline; September 2023) Updated 01 Sep 2023 |
| 28 Feb 2021 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Zika-virus-infection(Prevention) in USA Updated 28 Feb 2021 |
| 28 Feb 2021 | Phase Change - No development reported | No recent reports of development identified for research development in Zika-virus-infection(Prevention) in Brazil Updated 28 Feb 2021 |
| 28 Feb 2021 | Phase Change - No development reported | No recent reports of development identified for research development in Zika-virus-infection(Prevention) in Mexico Updated 28 Feb 2021 |
| 28 Jul 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Zika-virus-infection(Prevention) in Japan Updated 28 Jul 2020 |
| 28 May 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Zika-virus-infection(Prevention) in Argentina Updated 28 May 2020 |
| 28 Aug 2017 | Company Involvement | Protein Sciences Corporation has been acquired by Sanofi Updated 05 Sep 2017 |
| 12 Jan 2017 | Licensing Status | Protein Sciences and Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz) agree to co-develop Zika virus vaccine in Brazil for Zika virus infection (Prevention) [2] Updated 16 Jan 2017 |
| 12 Jan 2017 | Licensing Status | Protein Sciences and Laboratorios Liomont agree to co-develop Zika virus vaccine in Mexico for Zika virus infection (Prevention) before January 2017 [2] Updated 16 Jan 2017 |
| 12 Jan 2017 | Phase Change | Early research in Zika virus infection (Prevention) in Brazil (unspecified route) [2] Updated 16 Jan 2017 |
| 12 Jan 2017 | Phase Change | Early research in Zika virus infection (Prevention) in Mexico (unspecified route) [2] Updated 16 Jan 2017 |
| 12 Jan 2017 | Phase Change - Preclinical | Preclinical trials in Zika virus infection (Prevention) in USA (unspecified route) before January 2017 [2] Updated 16 Jan 2017 |
| 12 Jan 2017 | Trial Update | Protein Sciences plans a phase I trial for Zika virus infection (Prevention) in USA [2] Updated 16 Jan 2017 |
| 29 Jun 2016 | Phase Change | Early research in Zika virus infection (Prevention) in Japan (unspecified route) [3] Updated 16 Jan 2017 |
| 29 Jun 2016 | Licensing Status | Protein Sciences and UMN Pharma agree to co-develop Zika virus vaccine in Japan [3] Updated 05 Jul 2016 |
| 19 Apr 2016 | Phase Change | Early research in Zika virus infection (Prevention) in Argentina (unspecified route) [4] Updated 16 Jan 2017 |
| 19 Apr 2016 | Licensing Status | Protein Sciences, Sinergium and Mundo Sano enters into an agreement to develop a Zika virus vaccine [4] Updated 25 Apr 2016 |
| 19 Apr 2016 | Phase Change - Research | Research in Zika virus infection (Prevention) in USA (unspecified route) [4] Updated 25 Apr 2016 |
References
-
Sanofi completes the acquisition of Protein Sciences.
Media Release -
Protein Sciences Zika Vaccine Shows Good Results in Preclinical Testing.
Media Release -
UMN Pharma Joins Protein Sciences' International Zika Vaccine Consortium.
Media Release -
Protein Sciences Corporation, Sinergium Biotech and Mundo Sano Announce Zika Vaccine Partnership.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG